TIE2gether · Next-generation therapeutics for vascular diseases
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2027-02-01 → 2031-01-31
- Финансиране от ЕС
- 4 273 568 €
- Участници
- 15
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Сигнализиращият път TIE2 се изследва, за да се разбере как балансът му влияе върху състояния като диабетна васкулопатия и сепсис. Възстановяването на този баланс може да помогне за разработването на по-ефективни терапии при различни съдови заболявания.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
TIE2gether is a multidisciplinary research and training network addressing major unmet needs in vascular medicine.A wide range of vascular-related diseases—including chronic kidney disease, diabetic vasculopathy, sepsis, glaucoma and vascular malformations—affects millions and imposes a major societal and economic burden. Yet these conditions still lack effective, mechanism-based therapies. A unifying feature across these clinically distinct diseases is dysregulation of the TIE2 signalling cascade: hyperactivation drives vascular malformations while insufficient activity causes vascular leak, inflammation and organ dysfunction. Restoring balanced TIE2 signalling thus represents a major, largely unexplored therapeutic opportunity with relevance across both common and rare diseases.TIE2gether translates this opportunity into real-world benefit by training a new generation of scientists capable of bridging fundamental discovery with therapeutic innovation. The network brings together leading experts in vascular biology, organ-on-chip technologies, advanced disease modelling, chemical biology, protein engineering, and drug discovery. By centring around a single, highly druggable pathway, TIE2gether creates strong synergy and accelerates the transfer of mechanistic insight into validated therapeutic strategies evaluated in human-relevant systems.Fourteen Doctoral Candidates will gain cutting-edge competences in dissecting TIE2 signalling mechanisms, developing state-of-the-art disease models and designing and assessing next-generation therapeutics, including network-developed drug leads. Complemented by interdisciplinary, clinical and patient-facing training, they will acquire the innovation mindset, translational expertise and transferable skills needed across academia, industry and the biomedical sector. TIE2gether will deliver skilled researchers and novel therapeutic concepts to advance targeted treatments for vascular diseases with major societal impac
Оригинален текст от CORDIS (на английски).
Участници
- HELSINGIN YLIOPISTO · HelsinkiКоординаторФинландия
- BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION · KraainemБелгия
- BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG · ZwingenbergГермания
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN · BerlinГермания
- CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL · Bruxelles / BrusselБелгия
- DE DUVE INSTITUTE AISBL · Bruxelles / BrusselБелгия
- EUROPEAN MOLECULAR BIOLOGY LABORATORY · HeidelbergГермания
- GENEVIA TECHNOLOGIES OY · TAMPEREФинландия
- Night Science Institute LTD · New YorkНиво градСъединени щати
- Sang Biotech AB · UppsalaНиво градШвеция
- UNIVERSIDADE CATOLICA PORTUGUESA · LISBOAПортугалия
- UNIVERSITATSKLINIKUM BONN · BonnГермания
- UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEБелгия
- UNIVERSITY COLLEGE LONDON · LondonОбединеното кралство
- UPPSALA UNIVERSITET · UppsalaШвеция
Връзки
Данни: CORDIS, © Европейски съюз